Algernon Pharmaceuticals Strikes Deal to Advance Ifenprodil in Chronic Cough Treatment

Published on March 28, 2024 –News Direct–

Algernon Pharmaceuticals CEO Christopher Moreau joined Steve Darling from Proactive to announce a significant agreement regarding the company’s drug, Ifenprodil with U.S. Based Seyltx. Originally discovered in Japan and not utilized in the US or Europe, Ifenprodil was initially developed to treat intermittent claudication but found application in Japan for vertigo post-stroke. Dr. Mark Williams, Algernon’s co-founder, identified Ifenprodil’s potential for repurposing in new markets, particularly for Idiopathic Pulmonary Fibrosis (IPF) and chronic cough, a symptom associated with IPF.

During the interview, Moreau disclosed that the company has entered into a transformative agreement with a private US firm, granting them rights to advance Ifenprodil through a Phase 2b study targeting chronic cough. This agreement provides Algernon with a 20% interest in the acquiring company and a $2 million U.S. cash infusion. This financial injection strengthens Algernon’s financial position and enables it to focus on other projects, including a promising study on DMT for stroke treatment.

The agreement represents a pivotal moment for Algernon, positioning Ifenprodil for further development in a market with significant potential. Moreover, it allows Algernon to concentrate on advancing its broader drug development pipeline, ensuring the company remains at the forefront of innovation in the pharmaceutical industry.

In summary, the agreement concerning Ifenprodil marks a significant milestone for Algernon Pharmaceuticals, underscoring its commitment to advancing novel treatments and maximizing shareholder value. With a strengthened financial position and a focus on strategic initiatives, Algernon is well-positioned for future growth and success in the competitive pharmaceutical landscape.

Contact Details Proactive North America

Proactive North America

+1 604-688-8158

[email protected]

View source version on newsdirect.com: https://newsdirect.com/news/algernon-pharmaceuticals-strikes-deal-to-advance-ifenprodil-in-chronic-cough-treatment-714219688

News Direct is a content & news distribution platform purpose-built for the demands of strategic communications today. News Direct provides powerful performance advantages to help PR, Corp Comms and IR professionals excel in their media outreach efforts.

View This Press Release On

algernon-pharmaceuticals-strikes-deal-to-advance-ifenprodil-in-chronic-cough-treatment

Recent Press Releases

Press Release

Mission Statement

At Hexa PR Wire, our mission is to help businesses of all sizes achieve their marketing goals through high-quality press release distribution services. We believe that every business has a unique story to tell, and we are committed to helping our clients share their message with the world.

We are dedicated to providing exceptional customer service and ensuring that our clients’ press releases are distributed to the right people, at the right time, and in the right way.

Contact

Get immediate support by scanning the QR code below

Sitemap

Resources

Press Release Preparation: What We Need from You

The Power of Press Releases: Why Your Personal Brand or Company Needs Them

Submitting a Press Release with Hexa PR Wire

Guidelines For Publishing Your Press Release on Hexa PR Wire

What are Press Releases Intended For

Algernon Pharmaceuticals Strikes Deal To Advance Ifenprodil In Chronic Cough Treatment | Hexa PR Wire

Article Contents

In This Article

Recent News

The Power of a Component Search Engine

How Content Creator Tools Help to Keep You on Track

Driving Organizational Growth Using Skills Based Training

How Community Coworking Can Transform Your Business

Related Insights

Mission Statement

Contact

Sitemap